29 June 2023>: Articles
Endometrial Adenocarcinoma with Discordant Microsatellite Stability Status Treated with First-Line Pembrolizumab: A Case Report and Narrative Review
Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Rare coexistence of disease or pathology
Christopher R. Grant A* , Elaine J. Chiao E , Zhaohui L. Arter A , Cary Johnson C , Truc Tran B , Farshid Dayyani E , Krishnansu Tewari E , Valery Vilchez E , Joeseph Carmichael E , May Cho ADOI: 10.12659/AJCR.939448
Am J Case Rep 2023; 24:e939448
Figure 1. (A) Abdomen demonstrating 18.03×49.58 mm ill-defined retroperitoneal mass with invasion of the posterior third portion of the duodenum before the initiation of Pembrolizumab. (B) CT abdomen shows interval decrease ill-defined retroperitoneal mass size from 18.03×49.58 mm to 7.2×21.2 after 6 months of treatment with pembrolizumab.